Asset 2Asset 2Asset 2Asset 2
  • Capabilities
    • Trial Design and Management
    • Data Management
    • Regulatory and Quality
    • Consulting and Program Management
    • Biospecimens and Logistics
  • Expertise
    • Trial Types
    • Health Innovation Solutions
    • Clinical Applications
  • About Us
    • Company
    • Management Team
  • News & Events
  • Contact
✕
            No results See all results
            • Filter by
            • Categories
            • Tags
            • Authors
            • Show all
            • All
            • Events
            • GBC Blog
            • In Vitro Diagnostics - IVD News
            • Press Releases
            • All
            • All
            • neil.mucci@globalbioclinical.com
            July 24, 2019
            Published by admin on July 24, 2019
            Categories
            • GBC Blog

            Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

            Epigenomics AG, BERLIN, July 24, 2019 (GLOBE NEWSWIRE) — Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of […]
            Do you like it?0
            Read more
            July 23, 2019
            Published by admin on July 23, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            Curetis Files for U.S. FDA 510(k) Clearance of Unyvero Lower Respiratory Tract (LRT) Infection Assay for Bronchoalveolar Lavage (BAL) Specimens

            Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% […]
            Do you like it?0
            Read more
            July 12, 2019
            Published by admin on July 12, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            Epigenomics AG Receives MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics Award

            BERLIN and SAN DIEGO, (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 […]
            Do you like it?0
            Read more
            July 8, 2019
            Published by admin on July 8, 2019
            Categories
            • GBC Blog

            Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer

            Array BioPharma, based in Boulder, Colorado, announced positive results from its Phase III BEACON CRC trial. The trial evaluated a triple combination of Braftovi (encorafenib), a […]
            Do you like it?0
            Read more
            June 18, 2019
            Published by admin on June 18, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            New Clinical Data Support the Utility of Epi proColon Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

            Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its […]
            Do you like it?0
            Read more
            June 4, 2019
            Published by admin on June 4, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            New Data on Curetis Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

            Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, June 04, 2019 – Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA […]
            Do you like it?0
            Read more
            May 23, 2019
            Published by admin on May 23, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

            Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 23, 2019 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, […]
            Do you like it?0
            Read more
            May 21, 2019
            Published by admin on May 21, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon Blood Test

            Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based […]
            Do you like it?0
            Read more
            April 4, 2019
            Published by admin on April 4, 2019
            Categories
            • In Vitro Diagnostics - IVD News

            Curetis Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform

            Growing body of evidence shows benefits of Unyvero for antibiotic stewardship 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU […]
            Do you like it?0
            Read more
            Prev page
            1234567891011121314151617181920212223242526272829303132333435
            Next page

            Global BioClinical
            600 1st Avenue, Suite 330 PMB 80042
            Seattle, WA 98104-2246 USA

            Tel: +1 888 659 1221
            Fax: +1 206 299 9895
            Email: info@globalbioclinical.com

            Capabilities

            Trial Design and Management

            Data Management

            Regulatory and Quality

            Consulting and Program Management

            Biospecimens and Logistics

            Expertise

            Trial Types

            Health Innovation Solutions

            Clinical Applications

            About Us

            Company

            Management Team

            News & Events

            Contact

            © 2025 Global BioClinical. All rights reserved. | Privacy Policy

                      No results See all results
                      ✕